lonafarnib: Clinical Trials

4 trials of lonafarnib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Terminated 2

Follow lonafarnib: new trials by email Literature Review of lonafarnib trials Research Report on lonafarnib

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Lonafarnib, Ritonavir - Hepatitis D, Chronic
Phase 3CompletedSoroka University Medical Center102021-05-152026-04-30
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus
Phase 3CompletedEiger BioPharmaceuticals4072018-12-012023-04-14
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
Lonafarnib, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 3TerminatedMerck Sharp & Dohme LLC472005-05-012015-05-01
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
Lonafarnib (SARASAR) - Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Phase 3TerminatedMerck Sharp & Dohme LLC7022002-12-012015-08-27

Conditions studied

Hepatitis D (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Hepatitis B (1)  ·  Hepatitis D, Chronic (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasm Metastasis (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  Eiger BioPharmaceuticals (1)  ·  Soroka University Medical Center (1)

Countries

Israel (2)  ·  New Zealand (2)  ·  Turkey (Türkiye) (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Italy (1)  ·  Moldova (1)  ·  Mongolia (1)  ·  Pakistan (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Ohad Etzion, MD (1)

Results publications

PMID 37407002